Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?
暂无分享,去创建一个
W. Gerth | H. Eichler | S. Kong | B. Jönsson | P. Mavros
[1] A. Anell,et al. Health outcome measures used in cost-effectiveness studies: a review of original articles published between 1986 and 1996. , 2000, Health policy.
[2] A Gafni,et al. Opportunity costs and uncertainty in the economic evaluation of health care interventions. , 2002, Health economics.
[3] A. Garber,et al. Economic foundations of cost-effectiveness analysis. , 1997, Journal of health economics.
[4] A. Williams,et al. Calculating the global burden of disease: time for a strategic reappraisal? , 1999, Health economics.
[5] L. Doyal,et al. The rationing debate: Rationing within the NHS should be explicit: The case for , 1997 .
[6] Andrew R Willan,et al. Is there a kink in consumers' threshold value for cost-effectiveness in health care? , 2002, Health economics.
[7] M. Johannesson,et al. Cost-utility analysis from a societal perspective. , 1997, Health policy.
[8] M Johannesson,et al. Some reflections on cost-effectiveness analysis. , 1998, Health economics.
[9] M Emmelin,et al. How many lives is equity worth? A proposal for equity adjusted years of life saved. , 1998, Journal of epidemiology and community health.
[10] R. Klein. The case against , 1997, BMJ.
[11] Tammy O. Tengs,et al. One thousand health-related quality-of-life estimates. , 2000, Medical care.
[12] K. Phillips. Choices in Health Care , 1990 .
[13] C. Bulpitt,et al. Cost-effectiveness of the treatment of hypertension. , 1993, Clinical and experimental hypertension.
[14] Peter E. Hilsenrath,et al. The World Health Report 2000 , 2002 .
[15] W. Brouwer,et al. Rationalising rationing: economic and other considerations in the debate about funding of Viagra. , 2002, Health policy.
[16] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[17] M. Essink‐bot,et al. A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. , 2000, American journal of public health.
[18] D. Raisch. Understanding Quality-Adjusted Life Years and Their Application to Pharmacoeconomic Research , 2000, The Annals of pharmacotherapy.
[19] M. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.
[20] A. Gafni,et al. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. , 1993, Journal of health economics.
[21] J. Coast. Who wants to know if their care is rationed? Views of citizens and service informants , 2001, Health expectations : an international journal of public participation in health care and health policy.
[22] M. Johannesson,et al. Outcome measurement in economic evaluation. , 1996, Health economics.
[23] J. Coast,et al. The rationing debate: Rationing within the NHS should be explicit: The case for , 1997 .
[24] D. Schwappach,et al. Resource allocation, social values and the QALY: a review of the debate and empirical evidence , 2002, Health expectations : an international journal of public participation in health care and health policy.
[25] Maiwenn J Al,et al. Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. , 2003, Social science & medicine.
[26] Tammy O. Tengs,et al. Five-hundred life-saving interventions and their cost-effectiveness. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.
[27] M. Johannesson. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? , 2001, European heart journal.
[28] M Johannesson,et al. On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.
[29] Michael E. Chernew,et al. Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.
[30] R. McDonald. Street-level bureaucrats? heart disease, health economics and policy in a primary care group. , 2002, Health & social care in the community.
[31] N. Devlin,et al. Cost-effectiveness Thresholds: Economic and Ethical Issues , 2002 .
[32] T. Brewin. Monetary value of a human life. , 1978, British medical journal.
[33] B. New,et al. The Case Against , 2018, Journal of Pharmacy Practice and Research.
[34] J. Sachs. Macroeconomics and health: investing in health for economic development , 2002 .
[35] Frank A. Sloan,et al. Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .
[36] Milton C. Weinstein,et al. Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? , 1995 .
[37] Milton C. Weinstein,et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996 .
[38] A. Wagstaff. QALYs and the equity-efficiency trade-off. , 1991, Journal of health economics.
[39] A. Harris,et al. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996). , 2001, PharmacoEconomics.
[40] Alan D. Lopez,et al. The global burden of disease: a comprehensive assessment of mortality and disability from diseases injuries and risk factors in 1990 and projected to 2020. , 1996 .
[41] M. L. Gross. Ethics, Policy, and Rare Genetic Disorders: The Case of Gaucher Disease in Israel , 2002, Theoretical medicine and bioethics.
[42] A S Detsky,et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[43] L Sjöberg,et al. The Cost‐Effectiveness of Lifesaving Interventions in Sweden , 1997, Risk analysis : an official publication of the Society for Risk Analysis.
[44] David O. Meltzer,et al. Editorial: Some reflections on cost‐effectiveness analysis , 1998 .
[45] G H Mooney,et al. What is the monetary value of a human life? , 1977, British medical journal.
[46] Joseph E. Aldy,et al. The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World , 2003 .
[47] A Gafni,et al. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. , 1993, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[48] M. Johannesson,et al. Incorporating Future Costs in Medical Cost-Effectiveness Analysis , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.
[49] Graham Loomes,et al. Valuing Life Years and QALYs: Transferability and Convertability of Values Across the UK Public Sector , 2002 .
[50] Richard J. Zeckhauser,et al. Critical ratios and efficient allocation , 1973 .
[51] M A Hlatky,et al. Task force 6: cost effectiveness of assessment and management of risk factors , 1996 .
[52] Russ Kahan,et al. Opportunity costs , 1998 .
[53] I. Karlberg,et al. Opinions of Swedish citizens, health‐care politicians, administrators and doctors on rationing and health‐care financing , 2002, Health expectations : an international journal of public participation in health care and health policy.
[54] A H Briggs,et al. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. , 2001, Health economics.
[55] B. Levine,et al. Task Force 6: coronary artery disease. , 2005, Journal of the American College of Cardiology.
[56] M. Johannesson. The Concept of Cost in the Economic Evaluation of Health Care: A Theoretical Inquiry , 1994, International Journal of Technology Assessment in Health Care.
[57] J. Richardson,et al. Production gains from health care: what should be included in cost-effectiveness analyses? , 1999, Social science & medicine.
[58] J. Newhouse. US and UK health economics: two disciplines separated by a common language? , 1998, Health economics.
[59] A. Lees,et al. Deciding how NHS money is spent: a survey of general public and medical views , 2002, Health expectations : an international journal of public participation in health care and health policy.
[60] C. Ham. Retracing the Oregon trail: the experience of rationing and the Oregon health plan , 1998, BMJ.
[61] A. Culyer. Economics and ethics in health care , 2001, Journal of medical ethics.
[62] V. Fuster,et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. , 1996, Journal of the American College of Cardiology.